149 related articles for article (PubMed ID: 20816270)
21. Complications and limitations of drug therapy for Parkinson's disease.
Jankovic J
Neurology; 2000; 55(12 Suppl 6):S2-6. PubMed ID: 11188970
[TBL] [Abstract][Full Text] [Related]
22. [Motor symptoms in Parkinson disease].
Larsen JP; Beiske AG; Bekkelund SI; Dietrichs E; Tysnes OB; Vilming ST; Aasly JO
Tidsskr Nor Laegeforen; 2008 Sep; 128(18):2068-71. PubMed ID: 18846123
[TBL] [Abstract][Full Text] [Related]
23. Pharmacotherapy for Parkinson's disease.
Chen JJ; Swope DM
Pharmacotherapy; 2007 Dec; 27(12 Pt 2):161S-173S. PubMed ID: 18041936
[TBL] [Abstract][Full Text] [Related]
24. Management of motor complications in advanced Parkinson's disease.
Melamed E; Ziv I; Djaldetti R
Mov Disord; 2007 Sep; 22 Suppl 17():S379-84. PubMed ID: 18175400
[TBL] [Abstract][Full Text] [Related]
25. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
Stocchi F; Marconi S
Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
[TBL] [Abstract][Full Text] [Related]
26. How do you treat motor complications in Parkinson's disease: Medicine, surgery, or both?
Fahn S
Ann Neurol; 2008 Dec; 64 Suppl 2():S56-64. PubMed ID: 19127577
[TBL] [Abstract][Full Text] [Related]
27. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
28. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
[TBL] [Abstract][Full Text] [Related]
29. Optimizing pharmacotherapy: strategies to manage the wearing-off phenomenon.
Tse W
J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):12-7. PubMed ID: 17948614
[TBL] [Abstract][Full Text] [Related]
30. Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications.
Eggert K; Schrader C; Hahn M; Stamelou M; Rüssmann A; Dengler R; Oertel W; Odin P
Clin Neuropharmacol; 2008; 31(3):151-66. PubMed ID: 18520982
[TBL] [Abstract][Full Text] [Related]
31. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease.
Nyholm D
Expert Rev Neurother; 2006 Oct; 6(10):1403-11. PubMed ID: 17078781
[TBL] [Abstract][Full Text] [Related]
32. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease.
Hauser RA; McDermott MP; Messing S
Arch Neurol; 2006 Dec; 63(12):1756-60. PubMed ID: 17172616
[TBL] [Abstract][Full Text] [Related]
33. [Variance in effects of subthalamic nucleus stimulation].
Okiyama R; Yokochi F; Taniguchi M; Takahashi H; Hasegawa N; Hamada I
No To Shinkei; 2002 Oct; 54(10):883-8. PubMed ID: 12476577
[TBL] [Abstract][Full Text] [Related]
34. Current strategies in the treatment of Parkinson's disease and a personalized approach to management.
Diaz NL; Waters CH
Expert Rev Neurother; 2009 Dec; 9(12):1781-9. PubMed ID: 19951137
[TBL] [Abstract][Full Text] [Related]
35. [Initial management and adaptation of Parkinson's disease treatment].
Gérard JM
Rev Med Brux; 2008 Sep; 29(4):229-31. PubMed ID: 18949969
[TBL] [Abstract][Full Text] [Related]
36. Therapies in Parkinson's disease.
Jankovic J; Poewe W
Curr Opin Neurol; 2012 Aug; 25(4):433-47. PubMed ID: 22691758
[TBL] [Abstract][Full Text] [Related]
37. Drug selection and timing of initiation of treatment in early Parkinson's disease.
Schapira AH; Olanow CW
Ann Neurol; 2008 Dec; 64 Suppl 2():S47-55. PubMed ID: 19127579
[TBL] [Abstract][Full Text] [Related]
38. Continuous dopaminergic stimulation--from theory to clinical practice.
Antonini A
Parkinsonism Relat Disord; 2007 Sep; 13 Suppl():S24-8. PubMed ID: 17702632
[TBL] [Abstract][Full Text] [Related]
39. Diagnosis and Treatment of Parkinson Disease: A Review.
Armstrong MJ; Okun MS
JAMA; 2020 Feb; 323(6):548-560. PubMed ID: 32044947
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic and pharmacodynamic considerations in management of motor response fluctuations in Parkinson's disease.
Cedarbaum JM
Neurol Clin; 1990 Feb; 8(1):31-49. PubMed ID: 2181267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
